Serum Creatinine Levels in Children With Down Syndrome: A Single‐Centre Retrospective Study in Ireland Authors: C. Broderick Farrell, V. Peronace, A. Stokes, F. McGrane, E. Molloy, M. Riordan, J. Balfe Published: 2026 ABSTRACT ABSTRACTAimTo assess the proportion of children with Down syndrome (DS) with creatinine levels above standard paediatric reference ranges in a single‐centre Irish outpatient cohort.MethodsWe performed a retrospective cross‐sectional study of children aged 0–16 years attending the DS Clinic at Children's Health Ireland, Tallaght, between June 2022 and June 2024. Children with known renal disease and acute results were excluded. Creatinine levels were analysed using age‐ and sex‐specific reference ranges. The proportion with creatinine above the upper reference limit was compared with the expected proportion of 2.5% using a one‐sided exact binomial test. Estimated glomerular filtration rate (eGFR) was calculated using the bedside Schwartz equation, where height was available.ResultsA total of 194 patients were included. Among them, 52 (26.8%) had creatinine levels above the upper reference limit (p < 0.0001). Additionally, 42 (21.6%) had persistently elevated creatinine (p < 0.0001). Height was available for 124 children. Of those, 42 (34%) had an eGFR < 90 mL/min/1.73 m2 and 1 (0.8%) had an eGFR < 60 mL/min/1.73 m2.ConclusionChildren with DS in this Irish clinic frequently had creatinine levels above standard reference ranges. Further studies are required to clarify the clinical significance of these findings. Abbreviations Body mass index Congenital abnormalities of the kidney and urinary tract Congenital heart disease Children's Health Ireland Chronic kidney disease Down syndrome Estimated glomerular filtration rate Isotope dilution mass spectrometry Integrated Patient Management System Strengthening the Reporting of Observational Studies in Epidemiology Introduction Down syndrome (DS) is the most common congenital chromosomal abnormality, occurring in 1 in 444 live births in Ireland [1]. It is associated with multisystem involvement, including congenital heart disease, endocrine disorders, gastrointestinal atresias, and respiratory issues [2]. Children with DS are at increased risk of congenital abnormalities of the kidney and urinary tract (CAKUT), with a reported prevalence of 1.4%–4%, 4–5 times higher than the general population [3, 4, 5]. Reported abnormalities include hydronephrosis, anterior urethral obstruction, renal agenesis, hypospadias, posterior urethral valves, prune belly syndrome and cystic dysplastic kidney [3]. An increased risk of chronic kidney disease (CKD) with a prevalence of 4.5% has also been observed in children with DS [6]. Potential risk factors include higher rates of prematurity, congenital heart disease, obesity, and CAKUT. In addition, renal hypoplasia and lower estimated glomerular filtration rates (eGFR) have been reported in DS [7, 8]. Renal disease can impact quality of life for children with DS, with increased rates of hospitalisation for genitourinary conditions reported compared with the general population [9]. Renal imaging and biochemical testing are not routinely performed for children with DS unless clinically indicated [10]. With improved management of congenital conditions, particularly congenital heart disease, life expectancy in DS has increased [11]. As this population ages, renal function is increasingly clinically relevant. Higher serum creatinine levels have been associated with increased cardiovascular risk in adulthood [12]. Serum creatinine is widely used in clinical practice to assess renal function. However, its interpretation may be limited in populations with altered body composition, including children with DS, in whom differences in body composition and growth patterns may impact baseline creatinine levels [13, 14, 15]. This raises uncertainty about the applicability of standard paediatric reference ranges in this group. Two international studies (in Japan and France) have demonstrated higher creatinine levels among children with Down syndrome when compared with the general paediatric population, although differences between these populations suggest possible physiological, demographic, or ethnic variability [13, 16]. To date, no similar study has been published in an Irish population. The aim of this study is to assess the proportion of children with DS who have creatinine levels above the standard paediatric reference range in a single‐centre Irish outpatient cohort without pre‐existing renal disease. Methods Study Population We performed a single‐centre, retrospective, cross‐sectional study assessing serum creatinine levels among children with DS aged 0–16 years who attended the Down Syndrome Clinic at Children's Health Ireland (CHI) Tallaght, between June 2022 and June 2024. This clinic serves a general paediatric DS population in South Dublin and surrounding urban areas and is not a subspecialist referral clinic. A clinic list was generated using the Integrated Patient Management System (iPMS), which identified 277 total clinic attendees during the study period. Children were eligible for inclusion if they had at least one outpatient creatinine measurement performed at CHI Tallaght during the study period. Outpatient status was confirmed using laboratory source classification, with only samples originating from the “Paediatric Outpatient Department” included. Results from inpatient admissions or emergency department attendances were excluded. Patients with known renal disease or structural renal abnormalities were excluded. Predefined exclusion criteria for renal disease included CKD, CAKUT, hydronephrosis, and other documented renal abnormalities on imaging or in the medical record. A total of 5 patients (4 males and 1 female, aged 4–10 years) were excluded on this basis, with diagnoses/findings of vesicoureteric reflux, anterior urethral valves, thinning of the renal cortex, echogenic kidneys and hydronephrosis. A total of 194 patients were ultimately included for data analysis. A STROBE (Strengthening the Reporting of Observational Studies in Epidemiology)‐style flow diagram outlining cohort identification, exclusions and final analytical cohort is detailed in Figure 1. STROBE Flow Diagram of Patient Selection and Study Inclusion. Data Collection Ethical approval was obtained from the CHI Research Ethics Committee prior to starting data collection. Results of outpatient renal function tests of 194 children were collected using electronic patient records. The data were anonymised and logged on an Excel spreadsheet maintained on the hospital computer network. Clinic letters and discharge summaries were reviewed to identify comorbidities and collect anthropometric data (height and weight). All creatinine measurements were performed in the biochemistry laboratory of Tallaght University Hospital, which is co‐located with CHI Tallaght. Creatinine results from other centres were not included for analysis. The laboratory uses an isotope dilution mass spectrometry (IDMS)‐traceable enzymatic assay on the Roche C702 platform. No assay, reagent, or analyser changes occurred during the course of the study, between June 2022 and June 2024. Reference intervals are consistent with those recommended by the manufacturer, Roche Diagnostics. The intervals are derived from a study by Schlebusch et al. [17], which analysed serum samples from 521 healthy children in an outpatient setting to determine reference ranges for creatinine levels using an enzymatic method for creatinine analysis. While these reference ranges are manufacturer‐recommended and assay‐specific, they have not yet been independently validated for the paediatric population within our hospital. However, all creatinine measurements were performed using the same method and analytical platform throughout the study. Data Analysis Given the developmental variation in serum creatinine throughout childhood, patients were stratified into ten age‐specific groups based on the laboratory age‐ and sex‐specific creatinine reference ranges (Table 1) [17, 18, 19]. TABLE 1Creatinine Reference Ranges Based on Age.Age (years)Reference Range (μmol/L)< 114–341–215–313–423–375–625–427–830–479–1029–5611–1239–6013–1440–68F 15–1645–84M 15–1659–104 Creatinine Reference Ranges Based on Age. For the primary analysis, the first available creatinine level was used for each patient to ensure a uniform single‐timepoint comparison across the cohort and to avoid assumptions about measurement frequency. Patients were classified as having elevated creatinine if this first measurement was above their respective laboratory age‐ and sex‐specific creatinine reference range. As a sensitivity analysis, patients were classified as having persistently elevated creatinine only if all available measurements exceeded the age‐ and sex‐specific normal range, providing a more conservative test of the primary finding. EGFR was calculated using the bedside Schwartz equation for patients with available height data. Data were analysed using R statistical software version 4.4.1. The primary objective was to determine whether children with DS had higher‐than‐expected creatinine levels compared with the general population. Data analysis was carried out under the assumption that 2.5% of individuals would have creatinine levels above the upper limit of the reference range; this value (p = 0.025) was therefore used as the null hypothesis. This is consistent with the recommended reference range for the enzymatic creatinine assay, which defines the upper limit as the 97.5th percentile (Schlebusch et al.) [17]. Their study analysed creatinine levels in healthy children in an outpatient setting, comparable to the present study, which also included outpatient samples and excluded acutely unwell children. A one‐sided binomial test was conducted at a 5% significance level to investigate whether the observed proportion in the DS group exceeded this expected rate. Sample size calculations were also performed to estimate the number of participants required to detect various true proportions (alternative hypotheses) with 80% statistical power, as outlined in Table 2. TABLE 2Sample Size Calculation.True ProportionSample Size0.057140.101280.1563 Sample Size Calculation. Further analysis was performed to assess the relationship between congenital heart disease (CHD) and elevated creatinine levels. Due to the differences in age distribution between the two groups, direct comparisons were not made between children with CHD and those without. A one‐sided binomial test, restricted to children without CHD, was performed following the same procedure as the primary analysis. A Pearson's Chi‐square test with Yates continuity correction was then conducted to assess the association between CHD and elevated creatinine levels. Results A total of 277 patients attended the DS clinic between June 2022 and June 2024. Following exclusion of patients without outpatient creatinine levels and those meeting predetermined exclusion criteria, 194 patients were included in the final data analysis (Figure 1). Of those that met the inclusion criteria (n = 244), 80% (n = 194) had serum creatinine measurements available from outpatient attendances. One patient had outpatient blood results available, but serum creatinine was not performed. Baseline characteristics are described in Table 3. A total of 84 females (43%) and 110 males (57%) were included. All analyses were performed using age‐ and sex‐specific laboratory reference intervals. Mean creatinine levels are presented descriptively for comparison with laboratory reference ranges (Table 4). Mean creatinine values among the DS cohort exceeded the midpoint of the corresponding age‐ and sex‐specific reference ranges for all groups except children < 1 year and males 15–16 years. Both of these groups had a small sample size, n = 2 and n = 4, respectively. TABLE 3Baseline Characteristics.GroupNumber of patients (%) Total 194 (100) Age Category (years) < 12 (1)1–220 (10.3)3–431 (16)5–624 (12.4)7–830 (15.5)9–1030 (15.5)11–1225 (12.9)13–1423 (11.9)15–169 (4.6) Sex Female84 (43)Male110 (57) Comorbidities Congenital heart disease93 (48)Respiratory79 (40.7)Ear, nose and throat61 (31.4)Hearing loss49 (25.3)Endocrine26 (13.4)Gastrointestinal11 (5.7)Arthropathy10 (5.2)Coeliac disease7 (3.6)Neurological6 (3.1)Haematological5 (2.6) Baseline Characteristics. TABLE 4Mean Creatinine Levels.Age Category (years)Reference Range in μmol/L (Midpoint of Reference Range)Mean (number of patients)< 114–34 (24)22.5 (n = 2)1–215–31 (23)28.2 (n = 20)3–423–37 (30)32.9 (n = 31)5–625–42 (33.5)38.5 (n = 24)7–830–47 (38.5)45.7 (n = 30)9–1029–56 (42.5)51.2 (n = 30)11–1239–60 (49.5)55.1 (n = 25)13–1440–68 (54)62.1 (n = 23)F 15–1645–84 (64.5)71 (n = 5)M 15–1659–104 (81.5)76.3 (n = 4) Mean Creatinine Levels. Fifty‐two (26.8%) of 194 children with DS in this study had creatinine levels above the upper limit of their age‐ and sex‐specific reference range. This observed proportion (26.8%) was substantially higher than the 2.5% expected based on the laboratory reference interval. A one‐sided binomial test confirmed that this difference was statistically significant (p < 0.0001). Of 194 patients, 112 had only one creatinine measurement within the 2‐year study period, while 82 (42%) had at least two results. The mean first and last creatinine levels are summarised in Table 5. Forty‐two (21.6%) of 194 children had persistently elevated creatinine levels, defined as having all available creatinine measurements above the reference range. The observed proportion was higher than expected even under this stricter definition. A one‐sided binomial test confirmed that this difference was statistically significant (p < 0.0001). TABLE 5Mean of First and Last Creatinine Levels for Patients with Repeated Measurements.Age Group (Years)Midpoint of Reference Range (μmol/L)First Result Mean (number of patients)Last Result Mean (number of patients)< 12422.5 (n = 2)N/A1–22328.6 (n = 15)30.4 (n = 7)3–43032.8 (n = 16)32.3 (n = 14)5–633.539.4 (n = 9)38.9 (n = 16)7–838.544.7 (n = 13)45.8 (n = 10)9–1042.553.9 (n = 7)52.2 (n = 11)11–1249.557.2 (n = 13)60.9 (n = 10)13–145463.9 (n = 7)73 (n = 10)F 15–1664.5N/A72 (n = 1)M 15–1681.5N/A74 (n = 3) Mean of First and Last Creatinine Levels for Patients with Repeated Measurements. Height was available for 124 of 194 patients (64%). Further analysis, calculating eGFR, was performed for this subset. Forty‐two of the 124 patients (34%) had an eGFR < 90 mL/min/1.73 m2, while 1 patient (0.8%) had an eGFR < 60 mL/min/1.73 m2, indicating that clinically significant impairment was uncommon. Given the sample size of 194, the study was adequately powered to detect this difference, as supported by prior sample size analyses (Table 2). Due to sex‐specific reference ranges for creatinine, results are presented separately for females (Figure 2) and males (Figure 3). Mean Creatinine Levels Among Females with Down Syndrome. Mean Creatinine Levels Among Males with Down Syndrome. Ninety‐three patients (48%) had a history of CHD, which was the most common comorbidity. This includes any form of CHD, whether it required intervention or not. Of the children with CHD, 30.1% had elevated creatinine levels. Among the 101 children without CHD, 23.8% had elevated creatinine levels. When the analysis was restricted to children without CHD, a binomial test revealed a statistically significant proportion of individuals with elevated creatinine levels (p < 0.0001). Table 6 presents the distribution of creatinine levels in relation to CHD. There was no significant association between CHD and elevated creatinine level, as indicated by the Chi‐square test with Yates correction (p = 0.40). TABLE 6Creatinine Levels Relative to Congenital Heart Disease.Creatinine LevelNumber of patients with CHDNumber of patients without CHDAbove Upper Limit Normal2824Within Normal Reference Range6577 Creatinine Levels Relative to Congenital Heart Disease. Discussion Children in this Irish study frequently had serum creatinine levels above established paediatric reference ranges, despite exclusion of children with pre‐existing renal disorders known to affect renal function. This is consistent with findings from international studies conducted in France and Japan [13, 16]. Although creatinine values were frequently above the reference range, eGFR analysis demonstrated that significant renal impairment was uncommon, with just 0.8% (n = 1) having an eGFR < 60 mL/min/1.73 m2. The proportion of patients with an eGFR < 90 mL/min/1.73 m2 was higher at 34% (n = 42), although the clinical significance of this remains uncertain. A previous study of 54 patients with DS similarly reported an eGFR < 90 mL/min/1.73 m2 in 26% of patients and identified renal hypoplasia in 25% [7]. The discrepancy between patients with creatinine levels above the reference range and the very small number with significantly reduced eGFR (< 60 mL/min/1.73 m2) suggests that elevated creatinine values in children with DS do not necessarily reflect underlying CKD. Multiple factors may contribute to this finding, including body composition, developmental physiology, comorbidities, and possible limitations in the applicability of standard paediatric reference ranges to children with DS. Interestingly, a Japanese study aimed to establish creatinine reference intervals for children with DS, given the differences in physiology and growth trajectory among this population [16]. However, this was also a retrospective study and further prospective validation studies are required to determine whether DS‐specific reference ranges are appropriate and applicable within the local paediatric DS population. The primary analysis used the first available creatinine measurement to evaluate a consistent timepoint across all patients. However, given the potential for transient rise caused by clinical factors such as dehydration or intercurrent illness, a sensitivity analysis was performed to assess for persistent creatinine elevation. The proportion of patients with persistent elevation (21.6%) suggests that elevated creatinine levels were not attributable to transient variation in these patients. The proportion of children excluded from the study due to known underlying renal disorders (2.5%) was consistent with previously reported rates of CAKUT among this population [4, 5]. In addition, the prevalence of CHD in our cohort was comparable to rates reported in other DS populations [4, 5]. Adjustment for CHD as a potential confounding factor did not show a statistically significant difference in our results, suggesting that observed elevations in creatinine levels are not solely attributable to CHD. Strengths This study adds to the existing evolving literature relating to creatinine levels in children with DS. Creatinine levels were measured during annual paediatric review in children without known underlying renal disease and therefore may better reflect baseline outpatient creatinine levels than acute measurements that may be influenced by intercurrent illness. Additional strengths include the use of a single IDMS‐traceable enzymatic assay platform throughout the study period. It is the first study, to our knowledge, to assess creatinine levels among Irish children with DS. Limitations A key limitation of this study is its single‐centre, retrospective design, which restricts generalisability. A prospective, multicentre study incorporating detailed clinical and anthropometric data would allow for more robust adjustment for potential confounders. Although the overall sample size was adequate, representation was limited among children under 1 year and above 14 years of age, likely reflecting ongoing follow‐up with neonatology services in infancy or transition to general practice in adolescence. Given the substantial developmental variation in serum creatinine, particularly during early infancy, findings in these populations must be interpreted with caution. Inclusion in this study required at least one recorded creatinine measurement, introducing potential for selection bias. However, renal function testing (urea and creatinine measurement) was performed routinely for the majority of patients attending the clinic for annual review, with serum creatinine measurement available for 80% of eligible patients, which may reduce the extent of this bias. In addition, only one patient had blood results available from an outpatient annual review without a corresponding serum creatinine measurement, suggesting that creatinine measurement was routinely included when surveillance blood tests were performed. This study used reference ranges which are assay‐specific and used routinely by the local laboratory. However, they have not been independently validated in the local paediatric population, and so the assumption that 2.5% of a comparable healthy population would exceed the upper limit of the reference range must be interpreted with caution. Data on height and weight were incomplete, preventing adjustment for obesity as a potential confounding factor. Incomplete height data restricted the calculation of eGFR to a subset of patients, which may have impacted the interpretation of renal function across the cohort. Interestingly, a recent study found no significant association between body mass index (BMI), kidney size, and eGFR in children with DS, although the sample size in this study was small, with just 54 patients [7]. While obesity may influence creatinine levels or renal physiology in children with DS, other physiological or anatomical factors may play a more prominent role. Conclusion Our findings demonstrate that creatinine levels were frequently above standard paediatric reference intervals in this single‐centre, clinic‐based study of Irish children with DS. This is consistent with previous international studies reporting similar findings. However, these findings must be interpreted with caution as elevated creatinine levels may not necessarily reflect chronic kidney disease and may be influenced by multiple factors, including BMI, developmental physiology and reference interval applicability. Further prospective studies including urinalysis, blood pressure measurement, renal imaging and longitudinal follow‐up are required to clarify the clinical significance of our findings and determine the optimal approach to assessment of elevated creatinine in children with DS. Author Contributions F. McGrane: data curation. C. Broderick Farrell: writing – original draft, data curation, formal analysis, writing – review and editing, methodology. J. Balfe: supervision, conceptualization, writing – review and editing, methodology. E. Molloy: writing – review and editing. M. Riordan: writing – review and editing. A. Stokes: formal analysis, methodology. V. Peronace: data curation. Funding The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest.